Canada: Damages Reference: NIA Held To Not Be Available; Section 8 Damages Not Payable After Successful Infringement Claim (Intellectual Property Weekly Abstracts - Week Of October 16, 2017)

Patent Decisions

Damages reference: NIA held to not be available; section 8 damages not payable after successful infringement claim

AstraZeneca Canada Inc. v. Apotex Inc., 2017 FC 726

Drug: esomeprazole

The Federal Court recently issued the public decision in the reference on the patent infringement finding and the section 8 damages finding between AstraZeneca and Apotex. The section 8 case and the infringement case were heard separately, but the references were consolidated. The parties resolved most of their quantification issues prior to the hearing. The Court was left to determine whether: Apotex had a non-infringing alternative ("NIA"); how to reconcile the section 8 judgment with the infringement judgment, the allowance for profits on profits and the allowance for the United States District Court award for infringement.

In considering Apotex's NIA argument, the Court held that the onus rests on Apotex to prove that a NIA was available, and the cost of such an alternative. Apotex proposed a number of hypothetical formulations. However, the Court held that none of them had been shown to be approvable and commercially viable. Apotex was instead relying on extrapolation of data. The Court held that this approach was unacceptable. Apotex was asking the Court to predict a result it could have established itself. The Court was not prepared to draw those inferences. The Court considered all of the evidence put forward by the parties and held that Apotex had failed to establish on a balance of probabilities that it would have had an available NIA.

Apotex argued that its entitlement to damages as a result of the section 8 case should be set off against AstraZeneca's entitlement to damages in the infringement case. AstraZeneca argued that Apotex had not suffered any financial loss, but rather a lost opportunity to infringe its patent. In considering the arguments, the Court held that its discretion under section 8(5) must consider all of the circumstances bearing on the claim. The Court held that in order to recover any losses, Apotex would have necessarily had to infringe AstraZeneca's patent. Thus, if Apotex had entered the market during the section 8 period, it would have been required to disgorge its profits. As a result, Apotex was not entitled to recover any damages under section 8, as it had suffered no loss.

In considering profits on profits, the Court held that where it is not possible to know precisely how the infringer put its profits to use, it will be assumed to have made the most beneficial use of them, and compounded interest is the presumptive approach. No evidence was led as to how Apotex made use of its profits. The Court set the rate at prime compounded annually. Apotex did not disclose its tax statements, so no tax adjustment was made on the award of profits on profits.

Finally, the U.S. District Court had made an award to AstraZeneca for Apotex's infringement of an unrelated patent in the U.S. and the parties disagreed as to the legal effect of that judgment on recovery in these proceedings. Apotex was exporting esomeprazole to the United States that infringed the patent in this case. The Court held that AstraZeneca would be deprived of full recovery if Apotex does not have to disgorge any profits it made on U.S. exports. Thus, Apotex was ordered to disgorge all such profits less its portion of the U.S. judgment.

Allegations of obviousness and inutility found not justified

Pfizer Canada Inc. v. Teva Canada Limited, 2017 FC 777

Drug: PRISTIQ Form I ODV succinate

This application pursuant to the Patented Medicines (Notice of Compliance) Regulations involved allegations of obviousness and inutility. The reasons in an application resulting from a Notice of Allegation sent by Apotex Inc. related to the same drug were released separately (see 2017 FC 774, our summary here) and involved allegations of non-infringement, anticipation, double patenting, and overpromising arising out of section 27(3). The parties in the within application agreed on the construction of the asserted claims. The Court found that Teva's allegations of obviousness and inutility were not justified.

The Court set out the relevant considerations for an allegation of obviousness. The Court rejected Teva's argument that there is an over-arching inventive concept that applies to all the asserted claims. The Court determined the inventive concept of each asserted claim and then determined that a gap existed between the state of the art and the inventive concepts. The Court then considered whether the skilled person would have come directly and without difficulty to the solution taught by the patent. Teva argued that its witnesses were blinded but the Court considered this to be a question of relevance, reliability and weight, and concluded that a skilled person would not have come directly and without difficulty to the solution in the patent. The doctrine of obvious to try was applied by the Court, and the Court ultimately concluded that it was not more or less self-evident that what is being tried ought to work. Teva's allegation of obviousness was not justified.

In light of the Supreme Court's decision in AstraZeneca, the Court set out that the first question to be answered in respect of utility is to identify the subject-matter of the invention as claimed in the patent, and the second question is whether that subject-matter is useful. The Court also assessed utility on a claim by claim basis and found the allegations of inutility were not justified.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions